Compare Stocks

→ War Over Taiwan? Protect Your Wealth NOW (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLPH Bellerophon Therapeutics	$0.06 +0.2%	$0.05	$0.03 ▼ $11.15	$674K	0.67	59,889 shs	899 shs
NTEC Intec Pharma		$13.52	$8.80 ▼ $36.88	$8.65M	0.83	543,436 shs	988,300 shs
PRFX PainReform	$0.81 -3.5%	$1.69	$0.69 ▼ $26.41	$1.64M	0.53	116,004 shs	13,357 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLPH Bellerophon Therapeutics	+1.66%	-3.68%	-4.75%	-9.84%	-99.26%
NTEC Intec Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
PRFX PainReform	-2.08%	-5.71%	-53.38%	-58.46%	-85.15%

War Over Taiwan? Protect Your Wealth NOW (Ad)

With tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.

Access my report now >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLPH Bellerophon Therapeutics	2.1846 of 5 stars	3.0	0.0	0.0	4.8	3.2	0.0	0.6
NTEC Intec Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRFX PainReform	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLPH Bellerophon Therapeutics	2.00	Hold	$2.00	3,529.76% Upside
NTEC Intec Pharma	N/A	N/A	N/A	N/A
PRFX PainReform	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLPH Bellerophon Therapeutics	N/A	N/A	N/A	N/A	$0.27 per share	N/A
NTEC Intec Pharma	N/A	N/A	N/A	N/A	$16.18 per share	N/A
PRFX PainReform	N/A	N/A	N/A	N/A	$4.65 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLPH Bellerophon Therapeutics	-$19.83M	-$0.84	N/A	∞	N/A	N/A	-187.35%	-104.97%	5/13/2024 (Estimated)
NTEC Intec Pharma	-$14.13M	-$16.32	N/A	N/A	N/A	N/A	-96.37%	-68.87%	N/A
PRFX PainReform	-$9.34M	N/A	0.00	∞	N/A	N/A	N/A	N/A	5/20/2024 (Estimated)

Latest NTEC, BLPH, and PRFX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/26/2024	N/A	BLPH Bellerophon Therapeutics	N/A	-$0.42	-$0.42	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLPH Bellerophon Therapeutics	N/A	N/A	N/A	N/A	N/A
NTEC Intec Pharma	N/A	N/A	N/A	N/A	N/A
PRFX PainReform	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLPH Bellerophon Therapeutics	N/A	3.96	3.96
NTEC Intec Pharma	N/A	2.34	2.34
PRFX PainReform	N/A	4.07	4.07

Ownership

Institutional Ownership

Company	Institutional Ownership
BLPH Bellerophon Therapeutics	10.61%
NTEC Intec Pharma	22.37%
PRFX PainReform	37.28%

Insider Ownership

Company	Insider Ownership
BLPH Bellerophon Therapeutics	5.20%
NTEC Intec Pharma	3.30%
PRFX PainReform	34.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BLPH Bellerophon Therapeutics	18	12.23 million	11.60 million	No Data
NTEC Intec Pharma	40	898,000	N/A	Optionable
PRFX PainReform	7	2.03 million	1.33 million	Not Optionable

NTEC, BLPH, and PRFX Headlines

Source	Headline
	Short Interest in PainReform Ltd. (NASDAQ:PRFX) Increases By 232.9% americanbankingnews.com - April 26 at 1:54 AM
	PainReform Announces Closing of $4 Million Public Offering globenewswire.com - April 18 at 2:19 PM
	PainReform Announces Pricing of $4 Million Public Offering finance.yahoo.com - April 16 at 12:14 PM
	EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions msn.com - April 9 at 10:29 AM
	PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions finance.yahoo.com - April 9 at 10:29 AM
	PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions globenewswire.com - April 9 at 9:00 AM
	UK watchdog says Theramex-Viatris deal raises competition concerns finance.yahoo.com - April 4 at 10:18 AM
	Buy Rating Affirmed for PainReform as PRF-110 Shows Promise in Non-Opioid Pain Management Market markets.businessinsider.com - April 4 at 12:50 AM
	EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug finance.yahoo.com - April 2 at 11:02 AM
	PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy globenewswire.com - April 2 at 8:30 AM
	Buy Rating for PainReform’s PRF-110: Promising Non-Opioid Pain Solution Amidst Opioid Crisis markets.businessinsider.com - March 7 at 6:50 PM
	PainReform Provides Year-End Business Update globenewswire.com - March 1 at 8:00 AM
	PainReform to Present at the Microcap Conference in Atlantic City finance.yahoo.com - January 22 at 9:58 AM
	PainReform files to sell 968,545 ordinary shares for holders msn.com - January 12 at 8:33 PM
	Buy Rating for PainReform’s PRF-110: Superior Spreadability Signaling Market Advantage markets.businessinsider.com - January 5 at 9:56 AM
	PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief finance.yahoo.com - January 3 at 9:55 AM
	PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds finance.yahoo.com - December 26 at 9:38 PM
	PainReform Stock (NASDAQ:PRFX) Dividends: History, Yield and Dates benzinga.com - December 19 at 9:32 AM
	PainReform Ltd: PainReform Provides Business Update for the Third Quarter of 2023 finanznachrichten.de - November 19 at 10:09 AM
	Analysts Offer Insights on Healthcare Companies: PainReform (PRFX) and Tenet Healthcare (THC) markets.businessinsider.com - November 18 at 1:33 AM
	PainReform Provides Business Update for the Third Quarter of 2023 finance.yahoo.com - November 15 at 6:53 PM
	PainReform Ltd Ordinary Shares PRFX morningstar.com - November 12 at 10:51 AM
	PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate ... kentuckytoday.com - September 13 at 9:12 PM
	PainReform (PRFX) Gets a Buy from Maxim Group markets.businessinsider.com - September 12 at 6:58 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a month
April 26, 2024 3:21 AM
View Stock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a month
Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
April 25, 2024 10:36 AM
View Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
Pagaya Technologies: An AI Fintech That Insiders Are Buying
April 24, 2024 11:12 AM
View Pagaya Technologies: An AI Fintech That Insiders Are Buying

All Headlines

Company Descriptions

Bellerophon Therapeutics

NASDAQ:BLPH

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Intec Pharma

NASDAQ:NTEC

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.

PainReform

NASDAQ:PRFX

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial